Skip to content

Adalimumab

Humira (adalimumab) is an antibody pharmaceutical. Adalimumab was first approved as Humira on 2002-12-31. It is used to treat ankylosing spondylitis, crohn disease, hidradenitis suppurativa, juvenile arthritis, and psoriatic arthritis amongst others in the USA. It has been approved in Europe to treat ankylosing spondylitis, arthritis, crohn disease, hidradenitis suppurativa, and juvenile arthritis amongst others. The pharmaceutical is active against tumor necrosis factor.
Trade Name Humira
Common Name Adalimumab
ChEMBL ID CHEMBL1201580
Indication ankylosing spondylitis, arthritis, crohn disease, hidradenitis suppurativa, juvenile arthritis, papulosquamous skin diseases, psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, uveitis
Drug Class Monoclonal antibodies
Adalimumab
Get full access now